In: In vivo CAR-T
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- Reprograms the patient's own immune T cells, inside the body, to hunt one kind of cell, such as cancerous B cells. Standard CAR-T does this in a lab.In vivo CAR-T, mRNA in lipid nanoparticles, target not disclosed
- How it’s given
- “Dosing will begin at a lower dose level and may be escalated to dose levels considered safe and potentially effective according to the study protocol.”In the company’s words, NCT07629596 on ClinicalTrials.gov
- Tested for
- Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia (AIHA)
- Main trialEarly Phase 1
- “This is an open lable and single arm study designed to evaluate the safety, PK and PD of Arnovie101 in B cell-mediated Autoimmune Disease”In the company’s words, NCT07629596 on ClinicalTrials.gov
Coming up1
- 30 May 2027Early Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Early Phase 1Recruiting | 30 May 2027 | Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026